CLAIMS

1. A biomarker composition when used in diagnosis of anticancer drug sensitivity in a cancer cell, wherein the biomarker comprises RIP3 gene or a protein expressed from the gene.

2. A kit when used in diagnosis of anticancer drug sensitivity in a cancer cell, wherein the kit comprises a primer for amplifying RIP3 gene or an antibody or aptamer that binds specifically to a protein expressed from the gene.

3. Use of a receptor-interacting protein kinase-3 (RIP3) protein expression inducing agent or activator in the preparation of an anticancer adjuvant medicament for the treatment of cancer,

wherein the anticancer adjuvant enhances anticancer drug sensitivity in a cancer cell, and

wherein the cancer cell has lower expression or activity level of RIP3 protein compared to a normal tissue cell.

4. The use of claim 3, wherein the RIP3 protein expression inducing agent or activator is any one selected from the groups consisting of compounds, peptides, peptide mimetics, aptamers, antibodies and natural substances.

5. The use of claim 3, wherein the RIP3 protein expression inducing agent or activator is a demethylating agent

6. The use of claim 3, wherein the cancer is breast cancer, cervical cancer, liver cancer or colorectal cancer.